Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy

Br J Cancer. 2007 Dec 3;97(11):1465-8. doi: 10.1038/sj.bjc.6604049. Epub 2007 Oct 23.

Abstract

Celecoxib (Celebrex) was developed as a selective cyclooxygenase-2 (COX-2) inhibitor for the treatment of chronic pain. However, it now appears that this compound harbours additional pharmacologic activities that are entirely independent of its COX-2-inhibitory activity. This review presents the recently emerged direct non-COX-2 targets of celecoxib and their proposed role in mediating this drug's antitumour effects.

Publication types

  • Review

MeSH terms

  • 3-Phosphoinositide-Dependent Protein Kinases
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / therapeutic use*
  • Celecoxib
  • Cyclooxygenase 2 Inhibitors / chemistry
  • Cyclooxygenase 2 Inhibitors / therapeutic use*
  • Humans
  • Molecular Structure
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Protein-Serine-Threonine Kinases / antagonists & inhibitors
  • Protein-Serine-Threonine Kinases / metabolism
  • Pyrazoles / chemistry
  • Pyrazoles / therapeutic use*
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases / antagonists & inhibitors
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases / metabolism
  • Sulfonamides / chemistry
  • Sulfonamides / therapeutic use*

Substances

  • Antineoplastic Agents
  • Cyclooxygenase 2 Inhibitors
  • Pyrazoles
  • Sulfonamides
  • 3-Phosphoinositide-Dependent Protein Kinases
  • Protein-Serine-Threonine Kinases
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases
  • Celecoxib